Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to $351000.0.

  • Entrada Therapeutics' Current Deferred Revenue fell 9923.56% to $351000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $351000.0, marking a year-over-year decrease of 9923.56%. This contributed to the annual value of $13.7 million for FY2024, which is 8967.65% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Current Deferred Revenue of $351000.0 as of Q3 2025, which was down 9923.56% from $689000.0 recorded in Q2 2025.
  • Entrada Therapeutics' Current Deferred Revenue's 5-year high stood at $148.5 million during Q1 2024, with a 5-year trough of $351000.0 in Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median Current Deferred Revenue value was $60.5 million (recorded in 2024), while the average stood at $70.5 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Current Deferred Revenue surged by 2135.18% in 2024, and later plummeted by 9923.56% in 2025.
  • Quarter analysis of 3 years shows Entrada Therapeutics' Current Deferred Revenue stood at $132.3 million in 2023, then plummeted by 89.68% to $13.7 million in 2024, then plummeted by 97.43% to $351000.0 in 2025.
  • Its last three reported values are $351000.0 in Q3 2025, $689000.0 for Q2 2025, and $1.4 million during Q1 2025.